Hengrui Pharma and Novo Enter Exclusive License Agreement for Once-Weekly Oral GLP-1/GIP Dual Receptor Agonist HRS-1596
Why now
Thesis: Novo adds oral obesity candidate via license
Catalyst to watch: Phase I trial progress and milestones
Main risk: Early-stage drug may fail trials
Why it matters
A licensing deal for an oral GLP-1/GIP agonist expands Novo's obesity pipeline and validates the asset.
Details
HRS-1596 is a phase I-ready GLP-1/GIP dual receptor agonist for once-weekly oral dosing Total potential deal value is up to 2.6 billion US dollars, including 300 million dollars upfront, as well as potential sales royalties SHANGHAI, Sept. 29, 2026 /PRNewswire/ -- Hengrui Pharma...
Sources
- prnewswire · 2026-09-29 05:12 UTC